Form 8-K - Current report:
SEC Accession No. 0001193125-25-026192
Filing Date
2025-02-13
Accepted
2025-02-13 17:15:24
Documents
13
Period of Report
2025-02-10
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d385884d8k.htm   iXBRL 8-K 24887
  Complete submission text file 0001193125-25-026192.txt   146852

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ovid-20250210.xsd EX-101.SCH 2848
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ovid-20250210_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ovid-20250210_pre.xml EX-101.PRE 11260
15 EXTRACTED XBRL INSTANCE DOCUMENT d385884d8k_htm.xml XML 3633
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

EIN.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38085 | Film No.: 25621617
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)